Zsuzsanna Hortobagyi McMahan MD
Scleroderma & Related
Associate Professor of Medicine, Co-Director of the Scleroderma Center, UTHealth Houston
Join to view full profile
6410 Fannin StSte 450Houston, TX 77030
Phone+1 713-486-3100
Fax+1 713-500-0580
Dr. McMahan is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Johns Hopkins UniversityFellowship, Rheumatology, 2009 - 2012
University of Texas Southwestern Medical CenterResidency, Internal Medicine, 2006 - 2009
McGovern Medical School at UTHealthClass of 2006
Certifications & Licensure
TX State Medical License 2008 - 2027
MD State Medical License 2012 - 2023
NC State Medical License 2020 - 2022
PA State Medical License 2020 - 2022
American Board of Internal Medicine Rheumatology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 2 Certification Beacon Oncology 2014 Certified Module, Epic Systems Corporation, 2014, 2016-2017
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory - Core EMR, Epic Systems Corporation, 2014, 2016-2017
- CMS Meaningful Use Stage 2 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2014, 2016-2017
Publications & Presentations
PubMed
- A distinct gastrointestinal symptom profile characterizes clinically relevant fatigue in systemic sclerosis.Francesco Bonomi, Silvia Peretti, Giulia Bandini, Veronica De Silvestri, Cristiano Barbetta
Clinical Rheumatology. 2026-11-01 - Conceptual framework for the definition of disease modification in systemic sclerosis and potential implications for drug development and clinical study design.Jörg H W Distler, Shervin Assassi, Armando Gabrielli, Yannick Allanore, Lorinda Chung
Annals of the Rheumatic Diseases. 2026-11-01 - Emerging drugs in phase 2/3 and selected phase 1/2 cellular-therapy trials: a glimpse into the future of systemic sclerosis treatment.Eisha Naveed, Alain Lescoat, Marco Matucci-Cerinic, Masataka Kuwana, Christopher P Denton
Annals of the Rheumatic Diseases. 2026-10-23
Journal Articles
- Anti‐RNPC3 (U11/U12) Antibodies in Systemic Sclerosis Are Associated with Moderate to Severe Gastrointestinal DysmotilityRobyn T Domsic, Ami A Shah, Thomas A Medsger, Zsuzsanna H McMahan, Arthritis Care & Research
Authored Content
- Pyridostigmine for the Treatment of Gastrointestinal Symptoms in Systemic SclerosisJanuary 2018
Press Mentions
Clinical Science Sessions Full of New GuidelinesOctober 27th, 2022- Scleroderma & the Gut: New Frontiers in Diagnosis & Tips on ManagementMay 12th, 2022
What Is Scleroderma? These Are the Signs You Could Have ItDecember 24th, 2019
Grant Support
- Interrogating the pathophysiological mechanisms of constipation in patients with systemic sclerosisUNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON2023–2028
Other Languages
- Spanish, Hungarian
External Links
- Johns Hopkins Physicianshttp://www.hopkinsmedicine.org/zsuzsanna-mcmahan
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: